Clinical trials recruiting for Head and Neck Squamous Cell Carcinoma HNSCC
11
Recruiting trials
31
US states with sites
17
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Docetaxel | 2 |
| 5-FU (5-fluorouracil) | 1 |
| AK129(RP2D) | 1 |
| AK129(dose 1) | 1 |
| AK129(dose 2) | 1 |
| AP203 | 1 |
| Carboplatin | 1 |
| Cetuximab | 1 |
| DDI Probe Cocktail | 1 |
| EPI-326 | 1 |
| EXS74539 | 1 |
| GTAEXS617 | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 8 |
| Texas | 8 |
| New York | 6 |
| Ohio | 5 |
| Florida | 4 |
| Massachusetts | 3 |
| Michigan | 3 |
| New Jersey | 3 |
| Tennessee | 3 |
| Utah | 3 |
| Virginia | 3 |
| Arizona | 2 |
Top cities
New York, New York 5Houston, Texas 4Los Angeles, California 4Boston, Massachusetts 3Columbus, Ohio 3Nashville, Tennessee 3San Antonio, Texas 3Austin, Texas 2East Brunswick, New Jersey 2Fairfax, Virginia 2
Self-screener
Recruiting trials
- A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
- A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
- AK129 Combination Therapy for Advanced Solid Tumors
- Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Related conditions
Trials recruiting for Head and Neck Squamous Cell Carcinoma HNSCC often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Non-small cell lung cancer 507Pancreatic cancer 870Colorectal cancer 1359Breast cancer 2239Triple Negative Breast Cancer (TNBC) 35Prostate cancer 1234Ovarian cancer 118Gastric cancer 91Esophageal cancer 65
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Head and Neck Squamous Cell Carcinoma HNSCC trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.